摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 | 1226781-80-1

中文名称
2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑
中文别名
——
英文名称
2-methylsulfonyl-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole
英文别名
2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑化学式
CAS
1226781-80-1
化学式
C6H9N3O2S
mdl
——
分子量
187.222
InChiKey
BUJWKBIFOTURDW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    72.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑三乙酰氧基硼氢化钠溶剂黄146三氟乙酸 作用下, 以 二氯甲烷1,2-二氯乙烷甲苯 为溶剂, 反应 4.0h, 生成 (2R,3S,5S,6R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-6-(trifluoromethyl)tetrahydro-2H-pyran-3-amine
    参考文献:
    名称:
    TW2017/8222
    摘要:
    公开号:
  • 作为产物:
    描述:
    2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯苯磺酸 作用下, 以 醋酸异丙酯 为溶剂, 反应 48.0h, 以95%的产率得到2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑
    参考文献:
    名称:
    一种2-甲基磺酰基-2,4,5,6-四氢吡咯[3,4- c]吡唑苯磺酸盐的制备方法
    摘要:
    本发明公开了一种2‑甲酰氯‑2,4,5,6‑四氢吡咯[3,4‑c]吡唑苯磺酸盐的制备方法:(1)在原料I中加入溶剂A、DMF‑DMA,加热反应2‑4小时,冷却至室温,减压浓缩,得到红褐色固体,再用正庚烷打浆,降温,抽滤,得到产品II;(2)将产品II溶于溶剂B中,升温,滴加液体水合肼反应析出固体,反应完后降温至0℃以下抽滤得到固体III;(3)取固体III溶于溶剂C中,降温至0‑10℃,加入碱D和酰化剂E,将温度升至室温后搅拌2‑3h后,加入水淬灭,用盐酸调节pH在7‑8范围,分液萃取水相后得到的有机相经过洗涤、干燥后得到固体IV;(4)将固体IV用溶剂F溶解后,在常温下滴加PhSO3H,搅拌反应1‑2d后,抽滤得到固体产品V。
    公开号:
    CN105348286B
点击查看最新优质反应信息

文献信息

  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    申请人:Imago Biosciences, Inc.
    公开号:US20160237043A1
    公开(公告)日:2016-08-18
    Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    本文披露了新化合物和组合物,以及它们作为药物治疗疾病的应用。还提供了抑制KDM1A的方法,增加γ球蛋白基因表达的方法,以及诱导人类或动物主体中癌细胞分化的方法,用于治疗急性髓性白血病等疾病。
  • [EN] PROCESS FOR PREPARING CHIRAL DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'INHIBITEURS CHIRAUX DE DIPEPTIDYL PEPTIDASE-IV
    申请人:MERCK SHARP & DOHME
    公开号:WO2016014324A1
    公开(公告)日:2016-01-28
    A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of, reductive amination of:.
    制备结构式Ia化合物的过程:包括使用三氟乙酸对Boc进行去保护,还有还原胺化反应。
  • [EN] SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOPIPÉRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
    申请人:MERCK SHARP & DOHME
    公开号:WO2011037793A1
    公开(公告)日:2011-03-31
    The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ΪV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及结构式I的新型取代氨基哌啶,它们是二肽基肽酶-IV酶的抑制剂,并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用,如糖尿病,特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
  • [EN] SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS À SEPT CHAÎNONS EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE IV POUR LE TRAITEMENT DU DIABÈTE
    申请人:MERCK SHARP & DOHME
    公开号:WO2011146358A1
    公开(公告)日:2011-11-24
    The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及结构式(I)的新型氨基取代的七元杂环化合物,这些化合物是二肽基肽酶-IV酶的抑制剂,并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用,如糖尿病,特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
  • AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
    申请人:Biftu Tesfaye
    公开号:US20100120863A1
    公开(公告)日:2010-05-13
    The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及结构式I的新型取代氨基四氢吡喃衍生物,它们是二肽基肽酶-IV酶的抑制剂,可用于治疗或预防二肽基肽酶-IV酶参与的疾病,如糖尿病,特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-2-cyclopropyl-3-(trifluoromethyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5-isopropylaminocarbonyl-3-phenyl-1-polystyrenenethylaminocarbonyl-4,6-dihydropyrrolo[3,4-c]pyrazole 5-(6-{[(3,4-cis)-3-fluoropiperidin-4-yl]oxy}-5-methylpyrimidin-4-yl)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-1-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chloro-2-fluorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-2-ethyl-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one 5,5-dimethyl-2-(6-methylpyridin-2-yl)-3-(pyridine-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 5,5-dimethyl-2-(pyridin-2-yl)-3-(pyridin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 3-bromo-5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole 1-cyano-2,3,7-triazabicyclo[3.3.0]oct-2-ene 3-(aminomethyl)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid 1,1-dimethylethyl ester 5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-chlorophenyl)-1,3-dimethyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one 4-(4-chlorophenyl)-5-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-hydroxy-2-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one